Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
Original title: “AstraZeneca pulls plug on late-stage lung cancer trial, extending losing streak”
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
Original title: “New Taiho, Cullian data heats up lung cancer drug battle”
aumolertinib versus osimertinib as first line treatment for egfr mutant non small cell lung cancer a retrospective real world multicenter study
Original title: “Aumolertinib Versus Osimertinib as First-Line Treatment for EGFR-Mutant Non-Small Cell Lung Cancer: A Retrospective Real-World Multicenter Study.”
thyroid immune related adverse events following immune checkpoint inhibitors in nsclc insights from pharmacovigilance data a retrospective case control study and single cell rna sequencing dataset
Original title: “Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitors in NSCLC: Insights From Pharmacovigilance Data, a Retrospective Case-control Study, and Single-cell RNA Sequencing Dataset.”
Summit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing with a decision expected by Nov. 14.
Original title: “Summit has less than a year of cash runway left as PD-1/VEGF verdict nears”
Jideytro offers option for previously treated patients
Original title: “GSK wins US approval for ROS1 lung cancer therapy”
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
Original title: “GSK lung cancer drug gets speedy approval following $10.6B deal”
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.
Original title: “Merck ADC, in China study, shows potential to replace chemo in lung cancer”
Just weeks after Pfizer’s Seagen-acquired antibody-drug conjugate sigvotatug vedotin failed a Phase 3 non-small cell lung cancer study, the big pharma has quietly culled another program being developed by the ADC specialist.
Original title: “Pfizer scraps Seagen-developed ADC for solid tumors”
GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
Original title: “GSK, Hansoh ADC extends survival in lung cancer study”
paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features a diagnostic challenge a case report
Original title: “Paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features: a diagnostic challenge-a case report.”
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
Original title: “Merck, Gilead report mixed outcomes in key lung cancer, HIV studies”
While Merck and Gilead Sciences reported back-to-back late-stage victories for their weekly HIV pill, the partners also discontinued a Phase 3 program for their cancer combo after disappointing lung cancer survival data.
Original title: “Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble”
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
Original title: “Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?”
dynamic therapeutic response to osimertinib and immunotherapy in an egfr l747s and l858r co mutant nsclc
Original title: “Dynamic Therapeutic Response to Osimertinib and Immunotherapy in an EGFR L747S and L858R co-mutant NSCLC.”
alectinib and gastrointestinal perforation in alk rearranged non small cell lung cancer a case series
Original title: “Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case series.”
Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.
Original title: “ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come”
Practice-changing data in lung cancer, prostate cancer and more were on display over the weekend at the American Society of Clinical Oncology annual meeting in Chicago. Plus, early readouts on assets that could reshape the cancer landscape.
Original title: “ASCO: A battle of bispecifics, Eli Lilly’s big win and more”
“King Keytruda's reign continues,” analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics’ ivonescimab were revealed at the American Society for Clinical Oncology in Chicago.
Original title: “ASCO: Summit reached with China lung data but new climb begins to prove global benefit”
Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.
Original title: “ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer”